

Dr. Reddy's launches generic version of Ciprodex Otic Suspension

11 August 2020 | News

"We are pleased to launch this first-to-market generic product, illustrating our continued commitment to bringing affordable generic medicines to market for patients."



Dr. Reddy's Laboratories Ltd. (Dr.Reddy's), an Indian multinational pharmaceutical company based out in Hyderabad, recently announced the launch of Ciprofloxacin 0.3% and Dexamethasone 0.1% Otic Suspension, USP, a therapeutic equivalent generic version of Ciprodex® (ciprofloxacin 0.3% and dexamethasone 0.1%) Otic Suspension, approved by the U.S. Food and Drug Administration (USFDA).

Marc Kikuchi, Chief Executive Officer, North America Generics, Dr. Reddy's Laboratories commented, "We are pleased to launch this first-to-market generic product, illustrating our continued commitment to bringing affordable generic medicines to market for patients. At the same time, this product demonstrates that we are actively expanding the depth of our portfolio with our first otic suspension dosage form."

The Ciprodex® brand had U.S. sales of approximately \$453 million MAT for the most recent twelve months ending in June 2020 according to IQVIA Health*. Dr. Reddy's Ciprofloxacin 0.3% and Dexamethasone 0.1% Otic Suspension, USP, is available as 7.5 mL fill in a 10 mL bottle.